LEFKOS STAYROS/ The Athens Clinic and Mesogeios Dialysis Centers Group are conducting a joint study to investigate the development and evolution of immunity against the SARS-CoV-2 virus in a vaccinated dialysis population with vaccinated health workers. This is a prospective study examining the SARS-CoV-2 virus in the prism of molecular biology, immunology and other scientific areas in vaccinated dialysis versus vaccinated healthcare professionals. This study is carried out in relation to the medical staff of the dialysis units of the Mesogeios group, without excluding those who have been diagnosed with Covid-19.
Main objectives of the study:
- The main aim is the prevention of Covid-19 disease
- Measurement of antibodies against Sars Cov2 (binders or neutralizers) after vaccination
Secondary objectives of the study:
- Duration of immunity
- Side effects of the vaccine
- Avoid serious illness with Covid-19
- Death from Covid-19
The non-invasive study is carried out by collecting haematological material (through regular blood sampling) and nasopharyngeal cytological material (through appropriate nasal sampling) during dialysis in the Greek population compared to the control population (health workers).
The determination of the values of the various laboratory parameters to be examined is carried out using molecular biological and immunological techniques both in vaccinated hemodialysis (study group) and in vaccinated members of the medical staff (control group).
All laboratory tests are carried out in the Molecular Biology and Genetics Laboratory and Biopathology Laboratory of the White Cross Clinic in Athens.
The purpose of this study is to help the medical community obtain useful conclusions about the behavior of the SARS-CoV-2 virus, the response of the human body, and the effectiveness of antiviral vaccines in the vulnerable group of dialysis patients, as a part of the national vaccination program against COVID-19.
Important note: The participation in the above study is a voluntary and entirely personal decision.